Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 941

1.

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF.

Ungar L, Rodriguez F, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Singer DE, Patel MR, Piccini JP, Mahaffey KW.

Cardiol Ther. 2019 Aug 2. doi: 10.1007/s40119-019-00146-6. [Epub ahead of print]

PMID:
31376090
2.

The ESC Ethics Committee.

Breithardt G.

Eur Heart J. 2019 Jul 21;40(28):2284-2286. doi: 10.1093/eurheartj/ehz491. No abstract available.

PMID:
31327011
3.

Genome-wide association study suggests impact of chromosome 10 rs139401390 on kidney function in patients with coronary artery disease.

Schmitz B, Kleber ME, Lenders M, Delgado GE, Engelbertz C, Huang J, Pavenstädt H, Breithardt G, Brand SM, März W, Brand E.

Sci Rep. 2019 Feb 26;9(1):2750. doi: 10.1038/s41598-019-39055-y.

4.

Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.

Quinn GR, Hellkamp AS, Hankey GJ, Becker RC, Berkowitz SD, Breithardt G, Fava M, Fox KAA, Halperin JL, Mahaffey KW, Nessel CC, Patel MR, Piccini JP, Singer DE.

J Am Heart Assoc. 2018 Aug 7;7(15):e008755. doi: 10.1161/JAHA.118.008755.

5.

Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF.

Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR, Melloni C.

Eur Heart J Qual Care Clin Outcomes. 2019 Apr 1;5(2):145-152. doi: 10.1093/ehjqcco/qcy040.

PMID:
30219887
6.

Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study.

Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G, Bauersachs R, Wanner C.

BMJ Open. 2018 Sep 10;8(9):e022690. doi: 10.1136/bmjopen-2018-022690.

7.

Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey).

Erküner Ö, Dudink EAMP, Nieuwlaat R, Rienstra M, Van Gelder IC, Camm AJ, Capucci A, Breithardt G, LeHeuzey JY, Lip GYH, Crijns HJGM, Luermans JGLM.

Am J Cardiol. 2018 Aug 15;122(4):578-583. doi: 10.1016/j.amjcard.2018.04.053. Epub 2018 May 11.

8.

Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF.

Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR.

Am Heart J. 2018 Jun;200:102-109. doi: 10.1016/j.ahj.2018.02.013. Epub 2018 Feb 27.

PMID:
29898836
9.

Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.

Barnett AS, Cyr DD, Goodman SG, Levitan BS, Yuan Z, Hankey GJ, Singer DE, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hacke W, Mahaffey KW, Nessel CC, Fox KAA, Patel MR, Piccini JP.

Int J Cardiol. 2018 Apr 15;257:78-83. doi: 10.1016/j.ijcard.2017.06.110.

PMID:
29506743
10.

Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial.

Kochar A, Hellkamp AS, Lokhnygina Y, Jones WS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Singer DE, Piccini JP, Patel MR.

Clin Cardiol. 2018 Jan;41(1):39-45. doi: 10.1002/clc.22846. Epub 2018 Feb 1.

11.

Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference.

Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, Arnar D, Atar D, Auricchio A, Bax J, Benussi S, Blomstrom-Lundqvist C, Borggrefe M, Boriani G, Brandes A, Calkins H, Casadei B, Castellá M, Chua W, Crijns H, Dobrev D, Fabritz L, Feuring M, Freedman B, Gerth A, Goette A, Guasch E, Haase D, Hatem S, Haeusler KG, Heidbuchel H, Hendriks J, Hunter C, Kääb S, Kespohl S, Landmesser U, Lane DA, Lewalter T, Mont L, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Pison L, Potpara T, Ravens U, Richard-Lordereau I, Rienstra M, Savelieva I, Schnabel R, Sinner MF, Sommer P, Themistoclakis S, Van Gelder IC, Vardas PE, Verma A, Wakili R, Weber E, Werring D, Willems S, Ziegler A, Hindricks G, Kirchhof P.

Europace. 2018 Mar 1;20(3):395-407. doi: 10.1093/europace/eux318.

12.

Fatal attraction - A brief pathophysiology of the interaction between atrial fibrillation and myocardial ischemia.

Lieder H, Breithardt G, Heusch G.

Int J Cardiol. 2018 Mar 1;254:132-135. doi: 10.1016/j.ijcard.2017.11.119. Epub 2017 Dec 6. Review.

PMID:
29246425
13.

The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey.

Dudink EAMP, Erküner Ö, Berg J, Nieuwlaat R, de Vos CB, Weijs B, Capucci A, Camm AJ, Breithardt G, Le Heuzey JY, Luermans JGLM, Crijns HJGM.

Europace. 2018 Jun 1;20(6):929-934. doi: 10.1093/europace/eux217.

PMID:
29016989
14.

The need for specialized care for patients with Grown-up Congenital Heart Disease.

Breithardt G.

Eur Heart J. 2017 Mar 21;38(12):843-846. doi: 10.1093/eurheartj/ehx068. No abstract available.

PMID:
28931229
15.

Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR.

Am J Cardiol. 2017 Nov 15;120(10):1837-1840. doi: 10.1016/j.amjcard.2017.07.095. Epub 2017 Aug 7.

PMID:
28886856
16.

Patients' and procedural characteristics of AV-block during slow pathway modulation for AVNRT-single center 10year experience.

Wasmer K, Dechering DG, Köbe J, Leitz P, Frommeyer G, Lange PS, Kochhäuser S, Reinke F, Pott C, Mönnig G, Breithardt G, Eckardt L.

Int J Cardiol. 2017 Oct 1;244:158-162. doi: 10.1016/j.ijcard.2017.06.043. Epub 2017 Jun 15.

PMID:
28663043
17.

Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).

Washam JB, Hellkamp AS, Lokhnygina Y, Piccini JP, Berkowitz SD, Nessel CC, Becker RC, Breithardt G, Fox KAA, Halperin JL, Hankey GJ, Mahaffey KW, Singer DE, Patel MR; ROCKET AF Steering Committee and Investigators.

Am J Cardiol. 2017 Aug 15;120(4):588-594. doi: 10.1016/j.amjcard.2017.05.026. Epub 2017 May 29.

PMID:
28645473
18.

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.

Leef GC, Hellkamp AS, Patel MR, Becker RC, Berkowitz SD, Breithardt G, Halperin JL, Hankey GJ, Hacke W, Nessel CC, Singer DE, Fox KAA, Mahaffey KW, Piccini JP.

J Am Heart Assoc. 2017 Jun 14;6(6). pii: e004663. doi: 10.1161/JAHA.116.004663.

19.

Predisposing factors for atrial fibrillation in the elderly.

Wasmer K, Eckardt L, Breithardt G.

J Geriatr Cardiol. 2017 Mar;14(3):179-184. doi: 10.11909/j.issn.1671-5411.2017.03.010. Review.

20.

Transition in Patients with Congenital Heart Disease in Germany: Results of a Nationwide Patient Survey.

Helm PC, Kaemmerer H, Breithardt G, Sticker EJ, Keuchen R, Neidenbach R, Diller GP, Tutarel O, Bauer UMM.

Front Pediatr. 2017 May 19;5:115. doi: 10.3389/fped.2017.00115. eCollection 2017.

21.

Two-year outcome and risk factors for mortality in patients with coronary artery disease and renal failure: The prospective, observational CAD-REF Registry.

Engelbertz C, Reinecke H, Breithardt G, Schmieder RE, Fobker M, Fischer D, Schmitz B, Pinnschmidt HO, Wegscheider K, Pavenstädt H, Brand E.

Int J Cardiol. 2017 Sep 15;243:65-72. doi: 10.1016/j.ijcard.2017.05.022. Epub 2017 May 7.

PMID:
28526542
22.

Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Orgel R, Wojdyla D, Huberman D, Halperin JL, Breithardt G, Singer DE, Fox KAA, Hankey GJ, Mahaffey KW, Jones WS, Patel MR.

Circ Cardiovasc Qual Outcomes. 2017 May;10(5). pii: e003520. doi: 10.1161/CIRCOUTCOMES.116.003520. Review. No abstract available.

23.

Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).

Balla SR, Cyr DD, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR.

Am J Cardiol. 2017 Jun 15;119(12):1989-1996. doi: 10.1016/j.amjcard.2017.03.028. Epub 2017 Mar 29.

PMID:
28477860
24.

Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial.

Sun Y, Hu D, Stevens S, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Fox KAA, Patel MR.

Thromb Res. 2017 Aug;156:184-190. doi: 10.1016/j.thromres.2017.04.010. Epub 2017 Apr 13.

PMID:
28433206
25.

The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation.

Murphy A, Banerjee A, Breithardt G, Camm AJ, Commerford P, Freedman B, Gonzalez-Hermosillo JA, Halperin JL, Lau CP, Perel P, Xavier D, Wood D, Jouven X, Morillo CA.

Glob Heart. 2017 Dec;12(4):273-284. doi: 10.1016/j.gheart.2017.01.015. Epub 2017 Mar 21. Review.

26.

NOACs for Stroke Prevention in Atrial Fibrillation With Valve Disease: Filling the Gaps.

Breithardt G.

J Am Coll Cardiol. 2017 Mar 21;69(11):1383-1385. doi: 10.1016/j.jacc.2017.01.012. No abstract available.

27.

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.

Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, Mahaffey KW, Singer DE, Hacke W, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Becker RC, Fox KA, Patel MR; ROCKET AF Steering Committee and Investigators.

Circulation. 2017 Mar 7;135(10):1001-1003. doi: 10.1161/CIRCULATIONAHA.116.024666. No abstract available.

PMID:
28264892
28.

Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.

Shah R, Hellkamp A, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Fox KA, Nessel CC, Mahaffey KW, Piccini JP, Singer DE, Patel MR; ROCKET AF Steering Committee Investigators.

Am Heart J. 2016 Sep;179:77-86. doi: 10.1016/j.ahj.2016.05.019. Epub 2016 Jun 22.

PMID:
27595682
29.

Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.

Sherwood MW, Cyr DD, Jones WS, Becker RC, Berkowitz SD, Washam JB, Breithardt G, Fox KA, Halperin JL, Hankey GJ, Singer DE, Piccini JP, Nessel CC, Mahaffey KW, Patel MR.

JACC Cardiovasc Interv. 2016 Aug 22;9(16):1694-702. doi: 10.1016/j.jcin.2016.05.039.

30.

Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial.

Vemulapalli S, Hellkamp AS, Jones WS, Piccini JP, Mahaffey KW, Becker RC, Hankey GJ, Berkowitz SD, Nessel CC, Breithardt G, Singer DE, Fox KA, Patel MR.

Am Heart J. 2016 Aug;178:74-84. doi: 10.1016/j.ahj.2016.05.001. Epub 2016 May 6.

PMID:
27502854
31.

Sex differences in absolute myocardial perfusion. Non-invasive H2(15)O-PET in young healthy adults.

Range FT, Kies P, Schäfers KP, Breithardt G, Schober O, Wichter T, Schäfers MA.

Nuklearmedizin. 2016 Sep 26;55(5):196-202. doi: 10.3413/Nukmed-0821-16-04. Epub 2016 Jul 20.

PMID:
27437761
32.

Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".

Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR.

Circulation. 2016 Jul 12;134(2):e7-8. doi: 10.1161/CIRCULATIONAHA.116.022737. No abstract available.

33.

Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set.

Oto E, Okutucu S, Katircioglu-Öztürk D, Güvenir HA, Karaagaoglu E, Borggrefe M, Breithardt G, Goette A, Ravens U, Steinbeck G, Wegscheider K, Oto A, Kirchhof P.

Europace. 2017 Jun 1;19(6):921-928. doi: 10.1093/europace/euw144.

PMID:
27377074
34.

On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.

Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR; ROCKET AF Steering Committee and Investigators.

Circulation. 2016 Jul 5;134(1):37-47. doi: 10.1161/CIRCULATIONAHA.116.021890. Erratum in: Circulation. 2016 Aug 23;134(8):e114.

PMID:
27358435
35.

Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF.

DeVore AD, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR, Piccini JP; ROCKET AF Steering Committee and Investigators.

Europace. 2016 Aug;18(8):1135-42. doi: 10.1093/europace/euv404. Epub 2016 May 12.

36.

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.

Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators.

J Am Heart Assoc. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197.

37.

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.

Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Lokhnygina Y, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Califf RM, Fox KA, Patel MR; ROCKET AF Steering Committee & Investigators.

Heart. 2016 Jul 1;102(13):1036-43. doi: 10.1136/heartjnl-2015-308120. Epub 2016 Feb 17.

38.

Baseline Characteristics and Prescription Patterns of Standard Drugs in Patients with Angiographically Determined Coronary Artery Disease and Renal Failure (CAD-REF Registry).

Reinecke H, Breithardt G, Engelbertz C, Schmieder RE, Fobker M, Pinnschmidt HO, Schmitz B, Bruland P, Wegscheider K, Pavenstädt H, Brand E.

PLoS One. 2016 Feb 9;11(2):e0148057. doi: 10.1371/journal.pone.0148057. eCollection 2016.

39.

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.

Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FWA, Veltkamp R, Lip GYH.

Eur Heart J. 2017 Mar 21;38(12):860-868. doi: 10.1093/eurheartj/ehw069. Review.

40.

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.

Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FWA, Veltkamp R, Lip GYH.

Eur Heart J. 2017 Mar 21;38(12):852-859. doi: 10.1093/eurheartj/ehv643. Review.

41.

Three parties, one direction: Research priorities in adults with congenital heart disease. What do professionals, patients and relatives want to know?

Helm PC, Körten MA, Abdul-Khaliq H, Asfour B, Baumgartner H, Breithardt G, Kececioglu D, Schlensak C, Diller GP, Bauer UM.

Int J Cardiol. 2016 Mar 15;207:220-9. doi: 10.1016/j.ijcard.2016.01.027. Epub 2016 Jan 6.

PMID:
26803251
42.

Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation: Results From the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 Trial.

Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A, Eckardt L, Lewalter T, Breithardt G, Willems S; Gap-AF–AFNET 1 Investigators*.

Circ Arrhythm Electrophysiol. 2016 Jan;9(1):e003337. doi: 10.1161/CIRCEP.115.003337.

PMID:
26763226
43.

Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment.

Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J, Hatem S, Hidden-Lucet F, Kääb S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF, Schotten U, Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P.

Nat Rev Cardiol. 2016 Apr;13(4):230-7. doi: 10.1038/nrcardio.2015.194. Epub 2015 Dec 24. Review.

PMID:
26701216
44.

How can the European Society of Cardiology ensure compliance with ethical standards?

Simoons ML, Bassand JP, Bax J, Bertrand M, Breithardt G, Ferrari R, Fox K, Hugenholtz P, Komajda M, Pinto F, Rydén L, Tendera M, Vardas P.

Eur Heart J. 2016 Mar 1;37(9):741-4. doi: 10.1093/eurheartj/ehv651. Epub 2015 Dec 18. No abstract available.

PMID:
26685144
45.

Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.

Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR.

Circulation. 2016 Jan 26;133(4):352-60. doi: 10.1161/CIRCULATIONAHA.115.018544. Epub 2015 Dec 16.

46.

To the Editor--The role of advanced interatrial block pattern as a predictor of atrial fibrillation.

Baranchuk A, de Luna AB, Breithardt G.

Heart Rhythm. 2016 Mar;13(3):e87. doi: 10.1016/j.hrthm.2015.11.024. Epub 2015 Nov 17. No abstract available.

PMID:
26598323
47.

Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives.

De Sensi F, De Potter T, Cresti A, Severi S, Breithardt G.

Cardiovasc Diagn Ther. 2015 Oct;5(5):364-73. doi: 10.3978/j.issn.2223-3652.2015.06.03. Review.

48.

A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference.

Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, Heidbüchel H, Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Möller S, Kääb S, Kappenberger L, Kespohl S, Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Münzel F, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck G, Stoll M, Tavazzi L, Themistoclakis S, Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, Werring D, Willems S, Ziegler A, Lip GY, Camm AJ.

Europace. 2016 Jan;18(1):37-50. doi: 10.1093/europace/euv304. Epub 2015 Oct 18. Review.

PMID:
26481149
49.

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).

Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR, Becker RC, Breithardt G, Hacke W, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Piccini JP, Mahaffey KW, Fox KA; ROCKET AF Steering Committee and Investigators.

Am Heart J. 2015 Oct;170(4):675-682.e8. doi: 10.1016/j.ahj.2015.07.006. Epub 2015 Jul 17.

50.

Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany - results from the German AFNET registry.

Haeusler KG, Gerth A, Limbourg T, Tebbe U, Oeff M, Wegscheider K, Treszl A, Ravens U, Meinertz T, Kirchhof P, Breithardt G, Steinbeck G, Nabauer M; AFNET registry investigators.

BMC Neurol. 2015 Aug 5;15:129. doi: 10.1186/s12883-015-0371-8.

Supplemental Content

Loading ...
Support Center